Diagnostics and biomarker development: priming the pipeline
Related Experiment Video
Updated: Aug 8, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Kathryn A Phillips1, Stephanie Van Bebber, Amalia M Issa
1School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA. phillipsk@pharmacy.ucsf.edu
Abstract:
The decrease in the rate at which novel medical products are reaching the market, despite major scientific achievements and investment that might have predicted otherwise, is causing much concern. Although this 'pipeline problem' has often been discussed in the context of drug development, it is also crucial to examine the unique characteristics of the pipeline for biomarkers and diagnostics. Here, we characterize the pipeline problem for biomarkers and diagnostics, and consider what steps could be taken to solve it.
Related Concept Videos
Preclinical Development: Overview
Pharmacogenomics: Identification of New Drug Targets
Drug Discovery: Overview
